Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR   US68827R1086

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
16.9(c) 16.88(c) 16.51(c) 16.82(c) 16.13(c) Last
112 294 53 156 85 376 63 592 122 230 Volume
+0.06% -0.12% -2.19% +1.88% -4.10% Change
More quotes
Company
Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets.The company operates its business through two segments: Therapeutics and Biosurgery segment.The... 
More about the company
Surperformance© ratings of Osiris Therapeutics, Inc.
Trading Rating : - Investor Rating :
More Ratings
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 59,0 M
EBIT 2014 1,70 M
Net income 2014 -0,68 M
Debt 2014 -
Yield 2014 -
Sales 2015 85,9 M
EBIT 2015 11,3 M
Net income 2015 6,96 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015 80,65
Capi. / Sales 2014 9,37x
Capi. / Sales 2015 6,45x
Capitalization 554 M
More Financials
Latest news on OSIRIS THERAPEUTICS, INC.
01/02 OSIRIS THERAPEUTICS : Partners with Stryker
01/02 OSIRIS THERAPEUTICS : Joins Forces with Stryker for Marketing ' Viable Bone Matr..
01/01 OSIRIS THERAPEUTICS : Announces a Strategic Partnership with Stryker for Marketi..
2014 OSIRIS THERAPEUTICS : Entry into a Material Definitive Agreement, Regulation FD ..
2014 OSIRIS THERAPEUTICS : Announces a Strategic Partnership with Stryker for Marketi..
2014 OSIRIS THERAPEUTICS : Announces a Strategic Partnership with Stryker for Marketi..
2014 OSIRIS THERAPEUTICS : Appoints New Executives to Team
2014 OSIRIS THERAPEUTICS : Announces Expansion of the Leadership Team
More news
Sector news Bio Therapeutic Drugs
01/30 PHARMACYCLICS : Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for t..
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF